Concluding remarks: can we explain the association of beta-agonists with asthma mortality? A hypothesis
- PMID: 17085800
- DOI: 10.1385/criai:31:2:279
Concluding remarks: can we explain the association of beta-agonists with asthma mortality? A hypothesis
Abstract
Beta-agonists have clearly demonstrated benefits for the treatment of both acute and chronic asthma. Therefore, it is perhaps surprising that many of the articles in this issue have focused on concerns about their safety. Much of this concern can be traced back to the "beta-agonist controversy"--the association of high-dose isoprenaline and fenoterol inhalers with asthma mortality in the 1960s and 1970s. Although a causal link was never proven, lingering doubts about the safety of beta-agonists remain. It is unclear whether a similar adverse effect is responsible for recently reported association of long-acting beta-agonists with asthma deaths. No mechanism for the beta-agonist controversy was established, but the evidence presented in this collection of articles points to a number of contributing factors. I suggest that a combination of these effects provides a plausible mechanism for the association of frequent beta-agonist use with asthma mortality. Rebound bronchoconstriction and bronchial hyperresponsiveness occur on withdrawal of regular beta-agonist treatment. Regular use of fenoterol is associated with a reduction in morning peak flow suggesting that the overnight interval between doses is sufficient to allow rebound bronchoconstriction. This has not been observed with terbutaline or salbutamol, although rebound phenomena do occur when these drugs are withdrawn for slightly longer periods. Regular use of beta-agonists also leads to tolerance to their bronchoprotective and bronchodilator effects. Tolerance becomes more apparent with worsening bronchoconstriction. In severe asthma, this could result in a poor response to emergency treatment. The combination of rebound deterioration of asthma and a poor response to beta-agonist treatment resulting from tolerance could explain the increased mortality associated with fenoterol and isoprenaline. Both effects are probably caused by downregulation of beta-receptors which occurs with all beta-agonists. Long-acing beta-agonists cause a similar degree of tolerance to short-acting beta-agonists, but avoid the problem of overnight withdrawal. Long-acting beta-agonists have also been shown to improve asthma control when taken in combination with inhaled corticosteroids. The clinical significance of tolerance in this context remains to be determined.
Similar articles
-
Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled beta-agonist treatment.Respir Med. 2000 Aug;94(8):767-71. doi: 10.1053/rmed.2000.0820. Respir Med. 2000. PMID: 10955752 Clinical Trial.
-
Beta-agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality?J Allergy Clin Immunol. 1999 Aug;104(2 Pt 2):S18-30. doi: 10.1016/s0091-6749(99)70270-8. J Allergy Clin Immunol. 1999. PMID: 10452785 Review.
-
Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance?Br J Clin Pharmacol. 1992 Feb;33(2):129-38. doi: 10.1111/j.1365-2125.1992.tb04014.x. Br J Clin Pharmacol. 1992. PMID: 1347999 Free PMC article. Review.
-
Tolerance to beta-agonists during acute bronchoconstriction.Eur Respir J. 1999 Aug;14(2):283-7. doi: 10.1034/j.1399-3003.1999.14b08.x. Eur Respir J. 1999. PMID: 10515402 Clinical Trial.
-
The beta-agonist controversy.Med Clin North Am. 1996 Jul;80(4):719-48. doi: 10.1016/s0025-7125(05)70465-x. Med Clin North Am. 1996. PMID: 8676612 Review.
Cited by
-
Is overreliance on short-acting β2-agonists associated with health risks in the older asthma population?ERJ Open Res. 2022 Mar 28;8(1):00032-2022. doi: 10.1183/23120541.00032-2022. eCollection 2022 Jan. ERJ Open Res. 2022. PMID: 35350274 Free PMC article.
-
Whither autoimmunity: the lessons of anti-CCP and B cell depletion.Clin Rev Allergy Immunol. 2008 Feb;34(1):1-3. doi: 10.1007/s12016-007-8014-5. Clin Rev Allergy Immunol. 2008. PMID: 18270849
-
Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events.Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD007695. doi: 10.1002/14651858.CD007695.pub3. Cochrane Database Syst Rev. 2012. PMID: 22419326 Free PMC article.
-
Risks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey.BMJ Open. 2017 Sep 25;7(9):e016688. doi: 10.1136/bmjopen-2017-016688. BMJ Open. 2017. PMID: 28947448 Free PMC article.
-
Long-Acting β2-Agonists in Asthma: Enantioselective Safety Studies are Needed.Drug Saf. 2018 May;41(5):441-449. doi: 10.1007/s40264-017-0631-1. Drug Saf. 2018. PMID: 29332144 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical